Influenza B strain confirmed
Executive Summary
FDA's Vaccines & Related Biological Products Advisory Committee unanimously confirms its selection of Yamagata lineage Shanghai/361/2002-like influenza B strain for 2004-2005 vaccine by teleconference March 17. In February, the committee said the two influenza A strains in next season's flu vaccine should be a New Caledonia/20/1999 (H1N1)-like strain and a Fujian/411/2002 (H3N2)-like strain, but delayed a final decision on influenza B (1"The Pink Sheet" Feb. 23, 2004, p. 32)...
You may also be interested in...
Reverse Genetics Is Best Path To Cell Culture Vaccines – FDA Committee
Reverse genetics holds the greatest promise for developing cell culture-based vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Feb. 19
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.